drugset
drugset / Trial / NCT06562088

A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects

NCT06562088 ↗

Phase 1 Not yet recruiting 40 enrolled Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to characterize the effect of rifampicin and itraconazole on the PK of single dose of HDM1002 in healthy adult subjects. The safety and tolerability of HDM1002 and rifampicin or itraconazole when given separately or together will also be evaluated.

Timeline

Start
2024-08-16
Primary completion
2024-11-19
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HDM1002 Unknown — Oral
Subject Itraconazole Small molecule — Oral
Subject Rifampin Small molecule — Oral

Indications

No indication recorded.